Back to Agenda
Session 7 Track D: Biosimilars: What the Communicator Should Know About This Growing Field
Session Chair(s)
Lawrence Eugene Liberti, RAC
Director, D.K. Kim International Center for Regulatory Science, The Kim Center/ USC DRQS, United States
This session is aimed at regulatory writers and publications/medical communications writers who have an interest in preparing communications describing biosimilars products. The objective is to help participants recognize differences in communicating about the chemistry, pharmacology and other characteristics of biosimilars distinct from small molecules and generics.
Learning Objective : At the conclusion of this session, participants should be able to:- Recognize the differences between a biosimilars, small molecule, biologic and generic product
- Describe the special approaches required to communicate regulatory and clinical concepts regarding biosimilars
- Discuss the role of biosimilars in global health care
Speaker(s)
Matthew Frankel, MD, MBA
Executive Director, Medical Affairs Biopharmaceuticals North America, Sandoz Inc., United States
Eileen Girten, MS
Medical Writing Therapeutic Area Lead, Pfizer, United States
Lawrence Eugene Liberti, RAC
Director, D.K. Kim International Center for Regulatory Science, The Kim Center/ USC DRQS, United States
Have an account?